MUC1 and invasive breast carcinoma: The authors verified the specific recognition of tumor-associated MUC1 epitopes, human NK cell activation, and NK cell-mediated ADCC enhancement in vitro via the above antibodies, thus having the potential to be a therapeutic candidate for BRCA cellular immunotherapy.